Grace Anne Dorney Koppel Ignites Global Awareness Campaign for COPD, Challenging Smoking Stigma and Advocating for Broader Care

Grace Anne Dorney Koppel, widely recognized alongside her husband, the distinguished longtime anchor and managing editor of ABC News’ Nightline, Ted Koppel, is spearheading a passionate campaign to revolutionize public perception and understanding of Chronic Obstructive Pulmonary Disease (COPD). Diagnosed with the severe condition in 2001, Koppel has since dedicated herself to shedding light on the complexities of COPD, particularly aiming to dismantle the pervasive misconception that it is exclusively a smoker’s disease. Her resolute message challenges the ingrained societal adage, "Where there’s smoke, there’s fire," by asserting that "where there’s COPD, there’s not necessarily smoking." This crucial distinction underscores a vital truth: a significant portion of individuals afflicted with COPD have never smoked a single cigarette in their lives.

Koppel, who has been married to Ted Koppel since 1963, emphasizes the urgency of disseminating this information widely and elevating general awareness about COPD, which encompasses progressive lung diseases like emphysema and chronic bronchitis. Reflecting on her personal ordeal in a recent interview, she recounted the harrowing experience of her diagnosis: "I was diagnosed in 2001 with very severe COPD, and was not expected to live more than three to five years." Against all initial medical predictions, Koppel has remarkably defied these odds, living a vibrant life a quarter-century beyond her grim prognosis. However, she candidly acknowledges that the journey has been far from easy. Koppel describes COPD as "a lifelong progressive disease, and, of course, one never knows how long one has. But the progressive nature of it means that the breathlessness, the anxiety, the feeling that one is out of control, progresses as the disease progresses." This relentless advancement of symptoms underscores the profound physical and psychological toll the condition exacts on its sufferers.

The path to Koppel’s accurate COPD diagnosis in 2001 was fraught with medical oversights and frustrating delays, highlighting systemic issues in recognizing the disease. Initially, when experiencing debilitating symptoms, she sought help from her primary care physician. "I went to my family doctor, complaining of shortness of breath, inability to walk half a block as I had to stop and catch my breath," she recalled. Despite undergoing what her doctor termed a "complete physical," which even included a proctological examination, a fundamental diagnostic tool—a breathing test—was conspicuously omitted. Instead, she was given superficial advice: "He told me to lose 10 pounds, and I would feel like a new woman." This misdirection proved to be a critical setback, allowing her condition to worsen undetected.

The consequences of this initial misdiagnosis became devastatingly apparent just one month later. "A month later, I literally collapsed," Koppel recounted, detailing a vacation incident with her husband and children. "I was sitting up in bed at night. I couldn’t sleep, the wheezing sounds from my airwaves kept me awake." This alarming deterioration spurred her to take decisive action upon returning home. "When we got home, we made an appointment and went to a major medical center, and the first test they gave me was spirometry," Koppel stated, referring to a common lung function test. The results were stark and undeniable: "I was diagnosed with very severe COPD. So that’s how I was diagnosed. I had lost 72 percent of my ability to breathe." This profound loss of lung capacity indicated that the disease had advanced significantly before proper identification.

The revelation that her COPD had progressed to such a severe stage was profoundly shocking. COPD is characterized by a combination of inflammation and swelling in the airways and progressive damage to the alveoli—tiny, grape-like air sacs within the lungs crucial for the exchange of oxygen and carbon dioxide between the air and the bloodstream. As this damage accumulates over time, the lungs’ efficiency diminishes, making breathing increasingly difficult. Eventually, the damage can become so extensive that the lungs can no longer adequately supply oxygen to the body’s vital organs. For Koppel, this news was not only physically debilitating but also emotionally shattering.

Confronted with such a dire prognosis, Koppel described the emotional impact as having her "soul slapped." She was explicitly advised to "make end of life preparations." However, Koppel chose a different, more defiant path. "You can either throw yourself into rehabilitation, or you can say that’s it," she reflected. Her choice was resolute: "Instead, I tried to make life preparations." She credits her survival and improved quality of life to a confluence of factors: "I was fortunate that I had great doctors, that I had access to the medications that were available then and that I was able to go to pulmonary rehab, which was only a half hour away." This proactive approach, coupled with accessible, quality care, proved to be life-altering.

The decision to embark on "life preparations" is often easier said than done for individuals facing a disease that directly compromises the most fundamental human function: breathing. "It is not a nice disease because breath is life," Koppel emphasized with profound gravity. "It is light. And when you are deprived of breath, you’re deprived often of hope." While initial COPD symptoms might include mild shortness of breath, a persistent cough, wheezing, fatigue, or increased mucus production, Koppel’s advanced condition meant she was experiencing debilitating breathlessness, a symptom she identifies as the most significant disability reported by patients.

The progression of breathlessness is relentless, often escalating to the point where supplemental oxygen becomes necessary. "And it increases to the point where perhaps you need supplemental oxygen. Maybe you only need it when you’re moving, then you need it all the time," Koppel explained. The reliance on oxygen and increasing limitations on movement can lead to profound social and emotional challenges. "Then you are isolated and sometimes despised," Koppel noted, alluding to the societal stigma often associated with visible medical conditions and respiratory aids. "So it is a disease that is massive," she concluded, underscoring its widespread and multifaceted impact.

Koppel’s fortunate access to comprehensive medical care, a privilege many COPD patients lack, played a pivotal role in her ability to manage the disease. "Fortunately, I was treated aggressively. I was put on bronchodilators and oral steroids, and the best thing I was given a prescription for pulmonary rehab, that changed my life," she recounted. The road to recovery and regaining a semblance of normal life was arduous, but ultimately successful. "It was a long haul to getting back to where I truly could participate in life, but I was able to do it."

It is crucial to understand that COPD is not amenable to a singular, "magic bullet" cure. As Koppel aptly puts it, "This disease is not one where there’s the magic bullet or pill." Instead, effective management necessitates a holistic and proactive approach where the patient plays an integral role. "This is a disease where a patient has a part to play. We must do all the things that we want to avoid like exercise, nutrition, all of these things are important, and if you don’t exercise and keep active, the disease engulfs you." This emphasis on self-management, alongside medical interventions, is critical for slowing disease progression and maintaining quality of life.

Koppel frequently reiterates her gratitude for the care she has received and for having outlived her initial prognosis. However, she also acknowledges the relentless, progressive nature of COPD. "My day to day has changed over these years. Now, for the last 3 years, I’ve been on supplemental oxygen when I stand and when I move. I was not prior to that, so this has been an adjustment process," she shared. This increased reliance on oxygen necessitates meticulous planning and constant vigilance. "So now I have to carefully plan. If I’m going to the dentist, if I’m going to meet friends, I have to be sure I have enough battery. I have to worry about power failures. I have to worry about bad batteries. I have a whole group of things that I carry with me."

The heterogeneity of COPD further complicates treatment, as "there are not many models to follow because this disease is heterogeneous, it manifests itself in many different ways," Koppel explained. Despite the worsening of her breathlessness, her lung function has remained remarkably stable. "Yes, my breathlessness has gotten worse. However, I do hover around 50 percent of predicted lung function, sort of miraculous that after 25 years, when I started at 26 percent of a predicted lung function, But mine is not a typical story." Her atypical journey underscores the potential for aggressive management and patient adherence to yield extraordinary results, even in severe cases.

Inspired by her transformative experience with pulmonary rehabilitation and adherence to prescribed medications, Grace Anne Dorney Koppel and her husband established the Dorney-Koppel Foundation in 1999. This foundation became the driving force behind creating clinics designed to extend similar comprehensive care to others. "That started about 13 to 14 years ago," she recalled. Her realization of the profound benefits of pulmonary rehab spurred a critical question: why was this essential care not readily available in areas with the highest prevalence of COPD, particularly in rural America? Acting on this insight, the foundation began its work in West Virginia and has since expanded its network to 11 clinics. This initiative has not only provided vital resources to underserved communities but has also offered Koppel immense personal fulfillment. "It has given me enormous satisfaction to see people begin to take control of their own lives," she affirmed. "This has enriched my life and has given me purpose. To spread the message that COPD is not a death sentence. It’s a life sentence right now." Through these clinics, Koppel is actively fostering environments where proper care and treatment can flourish.

Beyond direct patient care, Koppel is dedicated to reshaping public discourse around COPD, vehemently challenging the perception that it is solely a "smoker’s disease." "It’s a disease that 25 to 40 percent of people who’ve never smoked get," she emphasized. Expanding on this, she highlighted the global reality: "And globally, it’s not a smoking disease. It’s a disease of the environment, of pollution, of occupation, of secondhand smoke." Koppel expressed profound concern over the escalating presence of environmental pollutants, noting that such contaminants, both indoors and outdoors, "potentially could be getting worse over time." She voiced worries about the weakening of The Clean Air Act and the insufficient attention given to the increasing frequency and intensity of wildfires, a topic that Forbes contributor Bruce Lee has extensively covered in recent years.

The global burden of chronic respiratory diseases, including COPD, is substantial yet often underestimated. Tedros Adhanom Ghebreyesus, PhD, Director-General of the World Health Organization (WHO), and José Luis Castro, the WHO Director-General Special Envoy for Chronic Respiratory Diseases, co-authored a poignant piece labeling chronic respiratory disease "the silent killer." They identified COPD as the world’s fourth leading cause of death, stating that "over 3 million lives are silently cut short by chronic obstructive pulmonary disease (COPD), a noncommunicable disease too often overlooked despite affecting over 380 million people globally." This stark reality underscores the urgency of Koppel’s advocacy.

This widespread overlooking of COPD has translated into significant underfunding for research and development. Koppel is a vocal advocate for increased support, hoping for a future where more effective treatments are discovered and brought to market. She cited the "promising Phase III clinical trial results for tozorakimab," AstraZeneca’s IL-33-targeting biologic, which demonstrated a reduction in moderate-to-severe COPD exacerbations. However, her ultimate goal is to see such innovative treatments become widely available and for the development of new biologics specifically tailored to target COPD.

The societal stigma surrounding COPD, largely due to its association with smoking, has historically deterred many well-known individuals from publicly sharing their struggles. This silence perpetuates the lack of awareness and understanding. Grace Anne Dorney Koppel, through her courage and unwavering commitment, is striving to break this cycle. Her efforts are not merely about her personal story but about breathing new life into global COPD awareness, prevention, and treatment initiatives, inspiring a collective push for better health outcomes for millions worldwide.